C P Reynolds
Overview
Explore the profile of C P Reynolds including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
3674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coothankandaswamy V, Cao S, Xu Y, Prasad P, Singh P, Reynolds C, et al.
Br J Pharmacol
. 2016 Oct;
173(23):3292-3306.
PMID: 27747870
Background And Purpose: Pancreatic cancer is a solid tumour that is often fatal. Hence, there is an urgent need to identify new drug targets for this disease. Highly proliferating cancer...
2.
Tagde A, Singh H, Kang M, Reynolds C
Blood Cancer J
. 2014 Jul;
4:e229.
PMID: 25036800
Melphalan (L-PAM) has been an integral part of multiple myeloma (MM) treatment as a conditioning regimen before stem cell transplant (SCT). After initial response, most treated patients experience relapse with...
3.
Cai W, Maldonado N, Cui W, Harutyunyan N, Ji L, Sposto R, et al.
Br J Cancer
. 2010 Oct;
103(9):1369-79.
PMID: 20924375
Background: The combination of temozolomide (TMZ) and irinotecan is a regimen used in neuroblastoma patients with recurrent disease. O(6)-methylguanine-DNA methyltransferase (MGMT) may have a function in resistance to TMZ. Using...
4.
Reynolds C, Perez-Polo J
Neurosci Lett
. 2009 Jul;
1(2):91-7.
PMID: 19604759
Rat C-6 glioma cells release a factor into culture medium which induces morphological differentiation in the IMR-32 human neuroblastoma cell line. The time course of differentiation and the effects on...
5.
London W, Castleberry R, Matthay K, Look A, Seeger R, Shimada H, et al.
J Clin Oncol
. 2005 Aug;
23(27):6459-65.
PMID: 16116153
Purpose: In the Children's Oncology Group, risk group assignment for neuroblastoma is critical for therapeutic decisions, and patients are stratified by International Neuroblastoma Staging System stage, MYCN status, ploidy, Shimada...
6.
Anderson C, Reynolds C
Bone Marrow Transplant
. 2002 Aug;
30(3):135-40.
PMID: 12189530
Patients with high-risk neuroblastoma (NB) initially respond to aggressive, alkylator-based therapy only to die from recurrent disease that is refractory to chemotherapy, including alkylating agents. We examined the ability of...
7.
ODonnell P, Guo W, Reynolds C, Maurer B
Leukemia
. 2002 May;
16(5):902-10.
PMID: 11986953
The retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR), mediates p53-independent cytotoxicity and can increase reactive oxygen species and ceramide in solid tumor cell lines. We determined changes in ceramide and cytotoxicity upon treatment with...
8.
Anderson C, Seeger R, Satake N, Keshelava N, Bailey H, Reynolds C
J Pediatr Hematol Oncol
. 2002 Mar;
23(8):500-5.
PMID: 11878777
Background: Alkylator resistance contributes to treatment failure in high-risk neuroblastoma. Buthionine sulfoximine (BSO) can deplete glutathione and synergistically enhance in vitro sensitivity to the alkylating agent melphalan (L-PAM) for many...
9.
Reynolds C, Lemons R
Hematol Oncol Clin North Am
. 2002 Jan;
15(5):867-910.
PMID: 11765378
In vitro studies that showed RA could cause growth arrest and differentiation of myelogenous leukemia and neuroblastoma led to clinical trials of retinoids in APL and neuroblastoma that increased survival...
10.
Keshelava N, Zuo J, Chen P, Waidyaratne S, Luna M, Gomer C, et al.
Cancer Res
. 2001 Aug;
61(16):6185-93.
PMID: 11507071
Neuroblastomas can acquire a sustained high-level drug resistance during chemotherapy and especially myeloablative chemoradiotherapy. p53 mutations are rare in primary neuroblastomas, but a loss of p53 function could play a...